Molecular map of liver disease could transform how MASLD is diagnosed and monitored
Peer-Reviewed Publication
Updates every hour. Last Updated: 29-Oct-2026 11:16 ET (29-Oct-2026 15:16 GMT/UTC)
Scientists mapped the molecular progression of MASLD, uncovering how biological processes driving liver damage change over time, creating a framework for more precise stage-specific therapies.
They identified a blood biomarker panel that predicts disease progression and outperforms current non-invasive diagnostic tools.
The work establishes a framework for precision monitoring and future development of targeted therapies for chronic liver disease.
Los Angeles, CA, July 14, 2026. More than 100,000 people in the United States are waiting for a lifesaving organ transplant. For patients in need of a liver transplant, determining whether a donor liver is healthy enough to transplant is a critical part of the process.
Prostate cancer is one of the most common cancers affecting men worldwide. However, planning personalized radiotherapy in the advanced stages of the disease still requires more precise tools. Researchers at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR) have now tested a novel approach. A combination of two diagnostic imaging techniques could pave the way for personalized radiotherapy. The results of the study, funded by the Wilhelm Sander Foundation, have been published in the Journal of Medicinal Chemistry (DOI: 10.1021/acs.jmedchem.6c00161).
Researchers tracked longitudinal alterations in adipose and muscle tissue through routine CT scans. Worsening visceral fat tissue degeneration predicts complications for compensated chronic hepatitis B-related cirrhosis, while sustained muscle loss signals risk in decompensated patients.
Ulinastatin (UTI), a protein naturally found in human urine, exerts hepatoprotective effects by attenuating inflammation, oxidative stress, and cell death, and modulating immunity and hemostasis. This review synthesizes existing evidence on UTI's therapeutic potential across seven liver conditions, from sepsis-induced hepatic injury to liver cancer.